XELOX + Bevacizumab Compared to FOLFOX4 + Bevacizumab in First Line Metastatic Colorectal Cancer in a Non-Reimbursed Health Care System: A Cost Analysis. Acta Med Philipp 2015, 49 (2). https://doi.org/10.47895/amp.v49i2.988.